An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Información del proyecto

Fucoderm

Identificador del acuerdo de subvención: 744737

DOI

10.3030/744737

Proyecto cerrado

Fecha de la firma de la CE 6 Diciembre 2016

Fecha de inicio 1 Diciembre 2016

Fecha de finalización 31 Marzo 2017

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

GLYCOMAR LIMITED
United Kingdom

Periodic Reporting for period 1 - Fucoderm (An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract)

Período documentado: 2016-12-01 hasta 2017-03-31

Resumen del contexto y de los objetivos generales del proyecto

GlycoMar intends to develop a novel topical cream for the management of mild to moderate eczema. The new product, ‘Fucobase’ will be suitable for long-term use and safe for both adults and children. The key objectives of the project are to finalise the Fucobase formulation, validate its safety and efficacy in humans, and commercialise the product as a CE certified medical device.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

Throughout the duration of the Phase I project, GlycoMar reviewed the product development plan, secured partners for further product development, expanded their knowledge of the eczema market and established a commercialisation strategy. The Phase 1 feasibility assessment established that a development plan for the Fucobase product is technically and commercially viable, and that implementation of an industrialisation and commercialisation plan should be pursued. SME Instrument Phase 2 funding could provide the correct amount of funding and support to allow the stated activities to be implemented successfully.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The proposed Fucobase product will provide mild to moderate eczema sufferers, with an effective, natural and universal treatment. Unlike many existing products, it will be suitable for use in both adults and children, due to minimal side effects. Fucobase will therefore contribute to a sustainable and innovative healthcare system in Europe by reducing the large medical and social costs caused by this common disease.

Fucobase